BASEL, Switzerland, Oct. 16, 2024 (GLOBE NEWSWIRE) -- BioVersys AG, a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for ...
Japan's Shionogi has added to its antibiotics pipeline by partnering a preclinical-stage candidate from Swiss biotech BioVersys, which specialises in drugs that can counter antimicrobial resistance ...
BASEL, SWITZERLAND - April 30, 2026 (NEWMEDIAWIRE) - BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial ...
BioVersys AG (SIX: BIOV), a multi-asset, clinical stage biopharmaceutical company focusing on research and development of novel antibacterial products for serious life-threatening infections caused by ...
BV500: Entered global research collaboration with Shionogi for broad-spectrum non-tuberculous mycobacteria Successful IPO funding operations into 2028 with BV100 Phase 3 read-out by the end of 2027 ...
BioVersys and Shionogi have entered a research and exclusive licence option agreement for the co-development of new ansamycin leads from the former’s BV500 programme into clinical candidates.
Swiss antibiotic developer BioVersys has launched an initial public offering, hoping to raise CHF 80 million ($88 million) to advance its pipeline of drug candidates for infections plagued by ...
Bioversys AG and Aptuit today announced the start of a joint collaboration aimed at the identification and validation of novel targets and molecules for Gram-negative bacteria. Aptuit and BioVersys ...
-- The Global Research Collaboration is a research and exclusive license option agreement with Shionogi to jointly develop novel ansamycin leads from BioVersys' BV500 program into clinical candidates ...
For development of first-in-class stand-alone anti-virulence small molecule drugs – a paradigm shift in AMR therapy CARB-X funds BioVersys up to US$ 8.92 million to support the development of first-in ...
BASEL, Switzerland, September 01, 2020 / B3C newswire / --BioVersys announces the successful completion of a CHF 19 million Series B financing round to advance its two lead assets of infectious ...
The Swiss pharmaceutical company BioVersys is developing next-generation antimicrobial drugs with unique modes of action targeting a range of multidrug-resistant bacteria. Antimicrobial resistance ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results